Medicines in pregnancy [version 1; peer review: 3 approved]

Medicine use in pregnancy is extremely common, but there are significant knowledge gaps surrounding the safety, dosage and long-term effects of drugs used. Pregnant women have been purposively excluded from clinical trials of the majority of treatments for conditions that may occur concurrently with...

Full description

Bibliographic Details
Main Authors: Sarah JE Stock, Jane E Norman
Format: Article
Language:English
Published: F1000 Research Ltd 2019-06-01
Series:F1000Research
Online Access:https://f1000research.com/articles/8-911/v1
_version_ 1818500582189563904
author Sarah JE Stock
Jane E Norman
author_facet Sarah JE Stock
Jane E Norman
author_sort Sarah JE Stock
collection DOAJ
description Medicine use in pregnancy is extremely common, but there are significant knowledge gaps surrounding the safety, dosage and long-term effects of drugs used. Pregnant women have been purposively excluded from clinical trials of the majority of treatments for conditions that may occur concurrently with pregnancy. There is minimal information on the pharmacokinetics of many existing treatments and no systematic capture of long-term outcome data to help inform choices. Treatments commonly used in pregnancy are thus often old and untested, not optimised in dose, and prescribed off-label without adequate safety information. In addition, there has been a staggering lack of investment in drug development for obstetric conditions for decades. This is a major public health concern, and pregnancy complications are the leading cause of mortality in children under five years old globally, and health in pregnancy is a major determinant of women’s long-term health and wellbeing. There is an acute need for adequate investment and legislation to boost inclusion of pregnant women in clinical studies, capture high-quality information on medication use in pregnancy in general, and encourage new medicinal product development for obstetric conditions.
first_indexed 2024-12-10T20:44:42Z
format Article
id doaj.art-ed831d3e3f8346c5bc2771b4cbf3c0ec
institution Directory Open Access Journal
issn 2046-1402
language English
last_indexed 2024-12-10T20:44:42Z
publishDate 2019-06-01
publisher F1000 Research Ltd
record_format Article
series F1000Research
spelling doaj.art-ed831d3e3f8346c5bc2771b4cbf3c0ec2022-12-22T01:34:16ZengF1000 Research LtdF1000Research2046-14022019-06-01810.12688/f1000research.17535.119177Medicines in pregnancy [version 1; peer review: 3 approved]Sarah JE Stock0Jane E Norman1Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Nine Edinburgh BioQuarter, 9 Little France Road, Edinburgh, EH16 4UX, UKMRC Centre for Reproductive Health, University of Edinburgh, Edinburgh BioQuarter, Edinburgh, EH16 4SA, UKMedicine use in pregnancy is extremely common, but there are significant knowledge gaps surrounding the safety, dosage and long-term effects of drugs used. Pregnant women have been purposively excluded from clinical trials of the majority of treatments for conditions that may occur concurrently with pregnancy. There is minimal information on the pharmacokinetics of many existing treatments and no systematic capture of long-term outcome data to help inform choices. Treatments commonly used in pregnancy are thus often old and untested, not optimised in dose, and prescribed off-label without adequate safety information. In addition, there has been a staggering lack of investment in drug development for obstetric conditions for decades. This is a major public health concern, and pregnancy complications are the leading cause of mortality in children under five years old globally, and health in pregnancy is a major determinant of women’s long-term health and wellbeing. There is an acute need for adequate investment and legislation to boost inclusion of pregnant women in clinical studies, capture high-quality information on medication use in pregnancy in general, and encourage new medicinal product development for obstetric conditions.https://f1000research.com/articles/8-911/v1
spellingShingle Sarah JE Stock
Jane E Norman
Medicines in pregnancy [version 1; peer review: 3 approved]
F1000Research
title Medicines in pregnancy [version 1; peer review: 3 approved]
title_full Medicines in pregnancy [version 1; peer review: 3 approved]
title_fullStr Medicines in pregnancy [version 1; peer review: 3 approved]
title_full_unstemmed Medicines in pregnancy [version 1; peer review: 3 approved]
title_short Medicines in pregnancy [version 1; peer review: 3 approved]
title_sort medicines in pregnancy version 1 peer review 3 approved
url https://f1000research.com/articles/8-911/v1
work_keys_str_mv AT sarahjestock medicinesinpregnancyversion1peerreview3approved
AT janeenorman medicinesinpregnancyversion1peerreview3approved